Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

iabetes, cognitive decline/dementia, nephropathy, atrial fibrillation and left ventricular hypertrophy.

Treatment arms for the ONTARGET(TM) trial were telmisartan 80 mg, ramipril 10 mg and a combination therapy with telmisartan 80 mg and ramipril 10 mg. All treatments were applied in addition to standard care for high-risk cardiovascular patients.

More than 700 sites throughout Asia, Australia, New Zealand, Europe, North/South America and South Africa participated in the ONTARGET Trial Program. The ONTARGET Steering Committee consists of scientists from McMaster University in Ontario, Canada; Oxford University in Oxford, England; the University of Auckland in Auckland, New Zealand; and Boehringer Ingelheim.

The ONTARGET trial was investigational and was conducted to expand scientific knowledge of telmisartan. Note that the trial included treatment for conditions outside the approved indication for telmisartan.

About Cardiovascular Disease

Cardiovascular disease (CVD) is the number one cause of death and disability globally(4) and is responsible for one of every three deaths worldwide -- an estimated 17 million people per year.(5) CVD causes more deaths than cancer, chronic respiratory disease and diabetes combined.(6) By 2020, it is predicted that CVD will surpass infectious diseases to become the largest cause of death and disability worldwide.(7) It is also contributes significantly to the escalating costs of health care. In 2006, the cost of CVD in the U.S. was estimated at $403.1 billion.(8)

Boehringer Ingelheim and Cardiovascular Medicine

Boehringer Ingelheim continues its century-long history of innovation and commitment to continuing research to further understand cardiovascular disease -- the number one cause of death worldwide. Boehringer Ingelheim has introduced novel agents in the management of hypertension and treatment of secondary stroke and continues to invest in a comprehensive cardiovascular pipeline.
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  IRIDEX Corporation (NASDAQ: ... second quarter 2014 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, July 31, 2014 ... other business developments. Interested parties may access ...
(Date:7/24/2014)... July 24, 2014 Omnicell, Inc. (NASDAQ: ... medication and supply management solutions and analytics software ... July 31, to discuss the Company,s Second Quarter ... Quarter 2014 earnings conference call and webcastWhen: ... Randall Lipps, chairman, president and chief executive officer ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based ... results for the second quarter ended June 30, 2014. ... of $6.5 million in the second quarter of 2014, an ... , Total revenues of $13.3 million for the six months ... same period in 2013 , Total revenues generated from ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... MicroCHIPS, Inc., a developer of innovative drug delivery ... Office and Trademark Office has granted U.S. Patent No. ... This patent in conjunction with U.S. Patent No. 7,070,590 ... reservoir-based medical devices used for implantable drug delivery systems. ...
... Promidian, a management consulting firm focused on ... survey findings about the increasing interest in the ... that is rapidly gaining nationwide attention for its ... care—while reducing costs. The Promidian ...
Cached Medicine Technology:MicroCHIPS Announces 35th U.S. Patent for Microreservoir-Based Drug Delivery Systems 2Promidian Survey Finds Growing Support for Patient-Centered Medical Home 2
(Date:7/27/2014)... 2014 This is a professional ... Dutasteride (CAS 164656-23-9) industry. The report firstly reviews ... its classification, application and manufacturing technology. The report ... Dutasteride (CAS 164656-23-9) listing their product specification, capacity, ... report further analyzes quantitatively 2009-2014 global and China’s ...
(Date:7/27/2014)... July 27, 2014 The report ... in Aviation - Market Analysis (Commercial Aviation And ... Pneumatic, Hydraulic, Mechanical) - Forecasts 2014 - 2019." ... are expected to shape the market during the ... and technology trends that are currently prevailing in ...
(Date:7/27/2014)... News) -- Couples aren,t more likely to get divorced ... new research finds. The study only looks at ... play a direct role in affecting whether couples stay ... speak against fears that women,s growing educational advantage over ... Schwartz, lead author of the study, said in an ...
(Date:7/27/2014)... July 27, 2014 Alta Resources ... outsourcing (BPO) for Fortune 500 brands, announced today that ... its locations in Wisconsin, California, Florida and the Philippines. ... several health-insurance clients, which have seasonal ramp-ups that require ... (AEP), November 2014 through February 2015. As more consumers ...
(Date:7/27/2014)... 27, 2014 The Institute of Safe ... adverse events such as Xarelto bleeding side-effects reported after ... out numbered the complaints filed for its competitor Pradaxa, ... for Xarelto increased to nearly 1 million prescriptions per ... early 2012, the ISMP noted in its latest issue ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 2Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 3Health News:Actuator Systems Market in Aviation Estimated to Reach $3,839.74 Million by 2019 - New Report by MarketsandMarkets 4Health News:Wives' Higher Education May Not Affect Divorce Rate 2Health News:Alta Resources to Fill Approximately 2,500 Positions 2Health News:Alta Resources to Fill Approximately 2,500 Positions 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 2Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 3Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 4Health News:Xarelto Lawsuit News: Report Finds Adverse Events For Xarelto Bleeding Side-Effects Outnumber Those For Pradaxa 5
... chronic hepatitis C are at risk of suffering from ... weeks from commencement of treatment, says the researchers in a ... Science (IOVS)in the January 2007 issue. ,Researchers from ... in diameter of blood vessels and the velocity of ...
... that suggests a link between a particular gene named ... journal, Neurobiology of Aging, published the results of the ... implicated in causing Alzheimer’s disease. ,This research now ... raises the possibility that occurrence of herpes infection earlier ...
... have to prescribe medicines by their generic names instead of ... ,"We have issued a letter in this regard to all ... and dispensaries," Singh told IANS. ,The doctors ... not the brand names. Failure to do so would call ...
... Leading pharmaceutical company Lupin Ltd has received tentative approval ... its generic drug Sertraline Hydrochloride for// treatment of major ... will be the AB-rated generic equivalent of Pfizer's Zoloft ... ,"The company intends to launch the generic (drug) ...
... were thought to be far cleaner and healthier as compared ... not true- inner cities are a haven// for unhealthy habits ... smoking and disease rates and dietary habits to understand the ... that towns such as Merthyr Tydfil in Wales happened to ...
... be used for 15 minutes before sleeping to treat insomnia ... based company Helicor, is under clinical trial on 100 patients ... heartbeat by regulated deep breathing, said the online edition of ... several other conditions including anxiety and panic attacks, is said ...
Cached Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
This product is for the lower body and uses a Convective Warming System which is both soft and comfortable. Constructed of 2-ply material consisting of polyethylene film inner layer and non-woven out...
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
CritiCool™ offers precise cooling to the programmed target temperature by applying temperature control algorithm....
Medicine Products: